Treats postpartum depression (PPD). Sold as Zurzuvae. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 1 application for Zuranolone (sold as Zurzuvae), first approved Aug 4, 2023, with 0 new uses approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Zurzuvae | Part D | $1.2M | +121% | 71 |
| A Long-Term Study of Patient-Reported Changes in Postpartum Depression Symptoms in People Starting ZuranolonePostpartum Depression · Biogen | — | Recruiting | Feb 10, 2026 |
| Allopregnanolone (Zuranolone) in Post-stroke DepressionPost Stroke Depression · Duke University | Phase 2 | Recruiting | Jan 6, 2025 |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
Biogen